Helomics: Interpace Diagnostics Partners With AI Specialist To Diagnose Thyroid Cancer

Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced it completed an agreement with the Helomics division of Predictive Oncology (NASDAQ: POAI), which is focused on applying artificial intelligence to personalized medicine and drug discovery.It's estimated that the treatment market for thyroid cancer was valued at approximately $340 million in 2018 ...Full story available on Benzinga.com